Arias Pharmaceuticals: A Case Study
In recent years, there has been an expansion of product development activities for colorectal cancer through a number of new public-private partnerships (PPPs). However, there is a lack of credible drug leads to feed the development pipeline of these PPPs and there is a great need for new drug discovery initiatives to produce such leads. There is a need to go beyond lead discovery and identify drug candidates that can be further developed.
Pharmaceutical companies often have relevant compounds that have not been assessed for their potential to treat colorectal cancer. The overall objective for this company, Arias Pharmaceuticals, is to help and support the discovery of new drug leads for colorectal cancer through networks and partnerships between pharmaceutical companies as well as academia. Specifically, the …show more content…
The primary objective of Arias Pharmaceuticals is to deliver new treatments by 2026 for colorectal cancer as well as to establish a strong R&D portfolio that addresses patient needs for treatment. Utilizing R&D networks, Arias Pharmaceuticals aims to bring medical innovation to the patients by developing:
- New drugs from novel compounds identified through screening and lead optimization
- Reformulations and combinations better adapted to field conditions (pediatric, long-acting, new route of administration, fixed-dose combinations, co-packaging, or co-administration);
- Existing drugs for target diseases (geographical extension of registration; completion of regulatory profiles of existing drug candidates).
Within 10 years, it is expected that there will
Pharmaceutical companies often have relevant compounds that have not been assessed for their potential to treat colorectal cancer. The overall objective for this company, Arias Pharmaceuticals, is to help and support the discovery of new drug leads for colorectal cancer through networks and partnerships between pharmaceutical companies as well as academia. Specifically, the …show more content…
The primary objective of Arias Pharmaceuticals is to deliver new treatments by 2026 for colorectal cancer as well as to establish a strong R&D portfolio that addresses patient needs for treatment. Utilizing R&D networks, Arias Pharmaceuticals aims to bring medical innovation to the patients by developing:
- New drugs from novel compounds identified through screening and lead optimization
- Reformulations and combinations better adapted to field conditions (pediatric, long-acting, new route of administration, fixed-dose combinations, co-packaging, or co-administration);
- Existing drugs for target diseases (geographical extension of registration; completion of regulatory profiles of existing drug candidates).
Within 10 years, it is expected that there will